Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Authors
Keywords
-
Journal
Endocrinology and Metabolism
Volume 37, Issue 4, Pages 575-586
Publisher
Korean Endocrine Society
Online
2022-08-30
DOI
10.3803/enm.2022.402
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70
- (2022) Brian A. Bergmark et al. CIRCULATION
- Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
- (2022) Ewa Karwatowska-Prokopczuk et al. Journal of Clinical Lipidology
- The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
- (2022) Yi Wen et al. Advanced Biology
- ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia
- (2021) Laurens F. Reeskamp et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs
- (2021) Takahito Doi et al. EUROPEAN HEART JOURNAL
- The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE−/−FXR−/− Mice
- (2021) Yenna Lee et al. Endocrinology and Metabolism
- Triglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation
- (2020) Jing Li et al. CLINICA CHIMICA ACTA
- Causes and Consequences of Hypertriglyceridemia
- (2020) Chris J. Packard et al. Frontiers in Endocrinology
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypertriglyceridemia—Causes, Significance, and Approaches to Therapy
- (2020) Leinys S. Santos-Baez et al. Frontiers in Endocrinology
- Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial
- (2020) Are Annesønn Kalstad et al. CIRCULATION
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
- (2020) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- Volanesorsen: First Global Approval
- (2019) Julia Paik et al. DRUGS
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
- (2019) Nam Hoon Kim et al. BMJ-British Medical Journal
- Clinical review on triglycerides
- (2019) Ulrich Laufs et al. EUROPEAN HEART JOURNAL
- New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
- (2018) Vesa M. Olkkonen et al. ATHEROSCLEROSIS
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- FAMILIAL CHYLOMICRONEMIA SYNDROME: A CLINICAL GUIDE FOR ENDOCRINOLOGISTS
- (2018) James M. Falko Endocrine Practice
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
- (2018) JoAnn E. Manson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
- (2016) James Backes et al. Lipids in Health and Disease
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting APOC3 in the Familial Chylomicronemia Syndrome
- (2014) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- (2013) Mark J. Graham et al. CIRCULATION RESEARCH
- Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
- (2013) John J.P. Kastelein et al. Journal of Clinical Lipidology
- Discovery and refinement of loci associated with lipid levels
- (2013) Cristen J Willer et al. NATURE GENETICS
- Mechanisms of Action of (n-3) Fatty Acids
- (2012) Philip C. Calder JOURNAL OF NUTRITION
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
- (2011) Uchechukwu K. Sampson et al. Current Atherosclerosis Reports
- Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
- (2011) Sung Hee Choi et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia
- (2010) Kiran Musunuru et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases
- (2007) Takamitsu Nakano et al. CLINICA CHIMICA ACTA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now